Cancer-inspired Genomics Mapper Model (CGMM)

• Cancer-inspired Genomics Mapper Model (CGMM) is a computational framework that integrates generative modeling and topological data analysis to mimic cancer evolution in genomic data.
• The model employs a reversed-bioprocess genetic algorithm with deep sequence encoding to simulate realistic mutation trajectories from healthy to disease states.
• CGMM utilizes Mapper graphs and spectral inference to identify tumor subtypes and uncover pathway-level molecular signatures for clinical insights.

The Cancer-inspired Genomics Mapper Model (CGMM) encompasses a set of computational and statistical frameworks for modeling, analyzing, and generating genomic sequences with disease- or phenotype-relevant signatures. These approaches synthesize topological data analysis, generative algorithms, and deep learning, explicitly leveraging insights from cancer evolutionary dynamics to inform the mapping from healthy to disease-associated genomic patterns. CGMM aims to address the intrinsic redundancy, high dimensionality, and complex structure of genomics data by integrating biologically plausible data transformations with rigorous inferential tools, facilitating both the in silico synthesis of genomes and the discovery of clinically relevant molecular subtypes (Lazebnik et al., 2023, Amézquita et al., 2022).

1. Model Formulations and Variants

CGMM has emerged in two principal formulations: (1) as a generative model for realistic synthetic genomes with user-specified signatures, and (2) as a topological data analysis (TDA) pipeline designed to uncover disease-relevant substructures within high-dimensional omics data (Lazebnik et al., 2023, Amézquita et al., 2022).

A. Generative CGMM (GA + DL Hybrid)

This implementation couples a reversed-bioprocess genetic algorithm (RBGA) with a sequence-to-sequence deep learning component:

• The RBGA evolves a population of control genomes toward a case (disease) genome, explicitly generating plausible mutational trajectories. The genomic distance metric, MASH, is used as the fitness criterion.
• The sequence of mutation steps is encoded using a deep AutoEncoder (AE) with a self-attention mechanism, which is then ingested by a recurrent neural network with long short-term memory (LSTM) units called the Next Mutation Predictor (NMP).
• The AE learns a compact latent representation of mutation trajectories; the NMP learns to autoregressively predict novel mutation sequences for unobserved controls.

B. Topological CGMM (Mapper-based)

In this version, CGMM exploits the Mapper algorithm to construct a graphical summary of RNA-seq data:

• Integration of per-sample Gaussian mixture model (GMM) normalization to produce standardized gene-level scores ($T_0$-score vectors).
• Mapper graphs constructed on "mean-correlation" filters delineate healthy and disease sub-cohorts, enabling unsupervised identification of tumor subtypes.
• Downstream differential expression and pathway analyses annotate subnetworks, while spectral signatures (heat-kernel signatures, HKS) are used for statistical inference on the resulting graphs (Amézquita et al., 2022).

2. Algorithmic Components and Workflow

The generative CGMM pipeline for synthetic genome generation is characterized by the following sequence of steps (Lazebnik et al., 2023):

1. Sample Partition and Pairing
   • Input VCFs are split into control and case (e.g., healthy vs. cancer) sets, with a proportion reserved for inference.
   • Each control is randomly paired with $z$ case samples to induce multiple putative mutation trajectories.
2. Mutation Path Generation (RBGA)
   • For each control–case pair, an RBGA population is initialized from the control sequence.
   • Fitness: $f(p_i) = \operatorname{MASH}(p_i, C)$; the process halts when the mean population MASH distance is below a threshold $\xi$.
   • Selection is via "tournament with royalty"; crossover is one-point at a random locus.
   • Mutations (SNP edits: add/delete/change) are applied according to an accelerated-bounded mutation schedule: $$\zeta_i \sim \operatorname{Normal}(\mu \lambda^i, \sigma^2 \lambda^i)$$. Large-effect mutations are rejected if exceeding threshold $\beta$.
   • Cases with known phenotype-associated SNPs bias edit probabilities accordingly.
3. Deep Sequence Encoding and Prediction
   • Mutation sequences, as ordered pairs $$(\text{position index}, \text{mutation code}\in[1,12])$$, are encoded by an AE tuned (via Bayesian optimization in AutoKeras) to a bottleneck size of 8192.
   • NMP (RNN-LSTM) is trained to predict next-step vectors, using categorical cross-entropy loss with end-of-sequence tokens.
4. Inference
   • For a new control genome: its latent representation is encoded, the NMP autoregressively predicts the latent mutation sequence, and the AE decodes it into SNP edits applied to generate the synthetic genome.
5. Evaluation
   • Synthetic genomes are compared to real datasets via hierarchical complete-linkage clustering (CLINK) on MASH distances.
   • Conversion rate measures the proportion of controls classified as "case" after mutation—in effect, the hemitransformation efficiency.

The topological CGMM workflow for tumor genomics proceeds as follows (Amézquita et al., 2022):

1. Batch Correction and GMM Fitting
   • Raw counts are batch-adjusted; per-sample log$_2$(FPKM+1) histograms are fit with two-component GMM.
2. Dimensionality Reduction and Lens Definition
   • Standardized $T_0$-score vectors are used to compute a "mean-correlation" lens for each sample.
3. Mapper Graph Construction
   • The lens value range is covered by overlapping intervals (typically $b=80$, $z$0 overlap).
   • Single-linkage agglomerative clustering is performed per interval with threshold $z$1.
4. Graph Augmentation and Analysis
   • Nodes (clusters) are annotated by tumor/healthy fraction and differential expression (via DESeq2).
   • Enrichment analysis uses Enrichr for GO/KEGG terms.
   • The Mapper graph supports definition of sub-populations, such as distinct tumor subtypes (position indices $z$2, $z$3).
5. Spectral Statistical Inference
   • The doubly-weighted Mapper graph yields a Laplacian, and heat-kernel signatures $z$4 are computed.
   • The graphical subject score (GSS) for each sample is the sum of HKS in its node memberships, facilitating statistical testing and sensitivity analysis.

3. Mathematical and Computational Foundations

Genetic Algorithm (RBGA)

• Population size: $z$5 (typically 100), generations: 100; mutation parameters: $z$6, $z$7 decrement, $z$8, royalty=0.05, $z$9, $f(p_i) = \operatorname{MASH}(p_i, C)$0 (Lazebnik et al., 2023).
• Fitness: alignment-free MASH distance computed via MinHash sketches $f(p_i) = \operatorname{MASH}(p_i, C)$1 and $f(p_i) = \operatorname{MASH}(p_i, C)$2.
• Accelerated mutation draws on analogies with cancer evolution: early high-magnitude steps annealing to smaller, localized edits.

Sequence Encoding

• Each mutation step is an integer pair, directly embedded via AE.
• Latent dimensionality (8192) is selected via Bayesian optimization.
• No explicit feature learning (one-hot, t-SNE, PCA); embedding is entirely data-driven.

Hierarchical Clustering and Evaluation

• CLINK applied to MASH distances; conversion rate is the evaluation metric.
• Comparisons across multiple tasks and baselines for statistical benchmarks.

Mapper and Topological Data Analysis

• Gaussian mixture scoring produces per-gene, per-sample standardized values ($f(p_i) = \operatorname{MASH}(p_i, C)$3), ensuring robust input for topology detection.
• The "mean-correlation" lens aggregates global similarities, supporting the preservation of sample topology.
• Construction of Mapper graphs preserves overlapping clusters and connects local structure via edge sharing.
• Heat-kernel signatures and the weighted Laplacian support spectral hypothesis testing.

4. Empirical Performance and Key Findings

CGMM demonstrates superior quantitative performance compared to current generators on ancestry and cancer genome synthesis tasks (Lazebnik et al., 2023):

• In multiple experiments across ancestry (PGP, ForenSeq) and cancer (UK, melanoma; Alexandrov 2020 SNPs), CGMM conversion rates span 78.3–86.6% for ancestry and 46.6–73.3% for cancer, with at most +15.6% gain upon providing locus knowledge (vs. up to +36% in shallow generators).
• Baseline methods (G2P, Zhou et al., PhenotypeSim., GEPSi) underperform both before and after integrating SNP distributions.
• In topological TDA applications, CGMM uncovers two discrete lung cancer sub-trajectories undetected by t-SNE or non-overlapping clusterers:
  • The PI=$f(p_i) = \operatorname{MASH}(p_i, C)$41 and PI=$f(p_i) = \operatorname{MASH}(p_i, C)$51 arms are enriched in immune/inflammatory and retinoid metabolism signatures, respectively.
  • Over 1700 dysregulated genes are shared, with an enrichment for muscle cytoskeletal processes, consistent with metastasis hypotheses (Amézquita et al., 2022).

5. Interpretation, Applications, and Limitations

CGMM’s generative and analytical pipelines serve complementary purposes:

• Synthetic genome generation supports data augmentation, rare-disease modeling, and robust validation under realistic mutational scenarios.
• Mapper-based TDA facilitates the discovery of pathway-level and subtype-specific signatures, with spectral scoring tools to enable statistical inference.

Limitations:

• The AE in generative CGMM is optimized strictly for sequential reconstruction; it does not incorporate explicit biological priors or genomic semantics (Lazebnik et al., 2023).
• The deep learning pipeline is a "black box" without model explainability, complicating the translation to clinical settings.
• Dataset scale remains limited in published results; larger and more diverse cohorts are needed for validation.
• The evolutionary dynamics embedded in the RBGA are inspired by cancer progression but may not generalize to all disease phenotypes without careful retuning of key parameters ($f(p_i) = \operatorname{MASH}(p_i, C)$6, $f(p_i) = \operatorname{MASH}(p_i, C)$7, $f(p_i) = \operatorname{MASH}(p_i, C)$8, $f(p_i) = \operatorname{MASH}(p_i, C)$9).
• The current TDA workflows, while topologically expressive, still rely on carefully chosen filter functions and clustering parameters whose robustness should be further characterized.

6. Context, Related Models, and Future Directions

CGMM’s integrative approach sets it apart from both earlier statistical simulators (using ad hoc variant distributions) and more recent multimodal contrastive models (Zhou et al., 2024). In the multimodal context, recent work leveraging Mamba-based genetic encoders and contrastive alignment to medical imaging (MGI) demonstrates the scalability of deep architectures for population-level genomic data. However, several methodological gaps remain for CGMM:

• Full hyperparameter transparency, especially in multimodal deep generative models.
• Incorporation of explicit positional, relational, or pathway-level priors.
• Robust multitask learning (segmentation, subspecies identification, survival prediction) using enriched objective functions.
• Expanded scaling to large, multi-institutional consortia and extension to other omics and imaging modalities.
• Enhanced explainability and model interpretability to bridge the gap between computational pipelines and clinical deployment.

Future development may include tighter integration of biological knowledge in model architectures, extension to spatial and imaging data, and adoption of more transparent and robust statistical frameworks for spectral inference and synthetic data benchmarking.

---

References:

• (Lazebnik et al., 2023) Cancer-inspired Genomics Mapper Model for the Generation of Synthetic DNA Sequences with Desired Genomics Signatures
• (Amézquita et al., 2022) Genomics Data Analysis via Spectral Shape and Topology
• (Zhou et al., 2024) MGI: Multimodal Contrastive Pre-training of Genomic and Medical Imaging